All News

biosimilars2.jpg

Best of 2019 - The Shame Behind Adalimumab Biosimilars

d Jack Cush, MD

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Read Article
choices2.jpg

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

d Jack Cush, MD

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Read Article
Clot.DVT_.VTE_.blood_.jpg

Best of 2019 - New EMA Warnings for Tofacitinib in Patients at Risk for Clots

d Jack Cush, MD

The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.

Read Article
guidelines.jpg (keep)

Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

d Jack Cush, MD

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axi

Read Article
Is the Serious infection (SIE) risk different between TCZ and TNFi? Not when used after failing 1 TNFi; But for biologic initiators, SIE risk was higher in TCZ compared to TNFi or ABA (based on claims data from 16074 TCZ matched to 33109 TNFi initiators https://t.co/ZHVWF9fIHF

Links:

Dr. John Cush RheumNow ( View Tweet)

Kaiser Permanente study of 1,956 adult #SLE patients shows that only 58% of lupus pts were ≥80% adherent to hydroxychloroquine. Only age and increasing visits were predictive. Not predictive were the rheumatologist, center or socioeconomic factors. https://t.co/m0oN1OC9bn

Links:

Dr. John Cush RheumNow ( View Tweet)

Since fasting is so hot right now, here is a hot off the press @NEJM review of it => Effects of Intermittent Fasting on Health, Aging, and Disease | NEJM https://t.co/Ijc0NSFa9s

Links:

Philip Robinson philipcrobinson ( View Tweet)

Should we keep our patients with #gout on colchicine indefinitely (if no contraindications/intolerances) for their higher risk of MI/CVD? https://t.co/4bQds3u1oL

Links:

Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)

The ACR and EULAR have developed the first-ever international set of classification criteria for IgG4-RD, which was established and tested using a data-driven approach and multicriterion decision analysis – details: https://t.co/rI8dRM8kmO https://t.co/sTJ360Ouxb

Links:

American College of Rheumatology ACRheum ( View Tweet)
Congrats & welcome new rheum fellows! Another competitive year, with rheum match rate (71.3%) behind GI (62.8%) but similar to CARDS (72.8%) & HONC (77.4%) Thankfully better than last year (65.1%) but still a lot of (well deserved!) excitement for the field! https://t.co/QDD5VCD8Rv
Mike Putman EBRheum ( View Tweet)
Patients and insurance companies in the United States pay higher prices for medications, imaging tests, basic health visits and common operations. https://t.co/oQrCSOE58j

Links:

NYT Health NYTHealth ( View Tweet)

#DidYouKnow Sir #WilliamOsler died ☠️ of what he called “the old man’s friend” (#pneumonia)? Learn more about the “father of #InternalMedicine” during the 💯th anniversary of his death https://t.co/0O61Qctouq. #IMProud @mcgillu @UniofOxford @JohnsHopkins @Penn @RoySocMed https://t.co/1ZS79pZrhx

Links:

ACP ACPinternists ( View Tweet)
The #Rheumatologist: Ellen M. Gravallese, MD, Begins ACR Presidency → https://t.co/ZO6ilPG0lk

Links:

American College of Rheumatology ACRheum ( View Tweet)

Exciting work by colleagues in US, led by NIH. https://t.co/bGB75bOGFB. immunodominant peptides of topo 1, fibrillarin, and centromere protein A are homologous to viral protein sequences from the Mimiviridae and Phycodnaviridae families, suggesting molecular mimicry.@NIH_NIAMS

Links:

Dr. Dinesh Khanna sclerodermaUM ( View Tweet)

Antiphospholipid syndrome incidence is 5 per 100k/Yr; lesser known complications include Libman Sachs valve dz, livedo reticularis, racemosa, skin ulcers/necrosis, GN, thrombotic microangiopathy, AVN, non-traumatic fractures https://t.co/rWlWZ39Lhd

Links:

Dr. John Cush RheumNow ( View Tweet)

The Best Rheums go to the Best Meetings - RHEUMNOW LIVE - March 13-14-15 2020 Great Venue =Fort Worth. Short Lectures, interactive sessions, Q&A panels, TED (like) Talks, digital, streaming and much more. You dont want to miss this meeting! https://t.co/69Y3QyU3Wc

Links:

Dr. John Cush RheumNow ( View Tweet)

Check out last weeks RheumNow Podcast - A Merry Lupus XMAS! videocast >> https://t.co/rFJQjVJIOc or the podcast >> https://t.co/blaXn1N5By

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 690 ambulatory patients examined RDW, ESR, CRP and showed RDW is increased in inflammatory disorders (RA, SpA) and elevated RDW has a 48–95% sensitivity and 66–95% specificity for inflammatory disease. https://t.co/dSdG1WTJY8

Links:

Dr. John Cush RheumNow ( View Tweet)

Using data mining and machine learning of medical/facility claims the estimated prevalence of myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS) in the U.S. is 1.7 million to 3.38 million - with 35-40% of patients being MEN. https://t.co/Urxbr3GIoH

Links:

Dr. John Cush RheumNow ( View Tweet)

2014-2015 study of 750K from Southern Sweden shows 24% of OA patients used opioids (2 fold higher than those without knee or hip OA).

Dr. John Cush RheumNow ( View Tweet)

×